Comoros vs Least developed countries: Access to anti-retroviral drugs, male
Comoros
98.0%
in 2024
Least developed countries
80.9%
in 2024
Comoros rank
1st
Least developed countries rank
2nd
Access to anti-retroviral drugs, male over time
- Comoros
- Least developed countries
How they compare
Comoros currently reports 98.0% against 80.9% in Least developed countries, a difference of 17.1%.
That makes Comoros's figure about 1.2 times Least developed countries's.
The two have swapped places 1 time across 25 shared years of data; in 2000 it was Least developed countries ahead.
Comoros ranks 1st and Least developed countries ranks 2nd of 141 countries.
Least developed countries has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Comoros | Least developed countries | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 5.7% | 5.7% | Least developed countries |
| 2010s | 26.4% | 40.1% | 13.7% | Least developed countries |
| 2020s | 67.4% | 73.4% | 6.0% | Least developed countries |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, male, Comoros or Least developed countries?
- Comoros, at 98.0% against 80.9% in Least developed countries as of 2024.
- What is the difference in access to anti-retroviral drugs, male between Comoros and Least developed countries?
- 17.1%, with Comoros ahead.
- How many years of comparable data are there for Comoros and Least developed countries?
- 25 years are reported by both, from 2000 to 2024.
- How do Comoros and Least developed countries rank globally for access to anti-retroviral drugs, male?
- Comoros ranks 1st and Least developed countries ranks 2nd of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, male (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult males living with HIV who are receiving antiretroviral therapy.